title: [Pyoderma gangrenosum with lung involvement treated with infliximab].
abstract: BACKGROUND
  Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis often associated with systemic diseases, particularly chronic inflammatory bowel diseases. Extracutaneous manifestations (articular, ocular, renal, pulmonary, hepatosplenic, muscular) exist, with lung involvement being the most common.
  
  
  METHODS
  We report a case of PG with skin and lung involvements in a patient treated with high-dose corticosteroids in a setting of severe ulcerative colitis (UC). Lung involvement was diagnosed during the pretreatment assessment performed prior to initiation of anti-TNFα therapy. Infliximab resulted in rapid improvement of the lung and skin lesions.
  
  
  CONCLUSIONS
  In the event of simultaneous cutaneous PG lesions and lung lesions suggestive of abscess, visceral involvement should be suspected. First-line treatment consists of oral corticosteroids. In our patient, the occurrence of lesions under corticosteroids in UC militated in favour of anti-TNFα therapy, which proved effective.
authors.affiliation: Service de dermatologie, université de Lille-2, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonovski, 59037 Lille cedex, France. delphine.deregnaucourt@gmail.com
authors.forename: D
authors.initials: D
authors.lastname: Deregnaucourt
authors.forename: S
authors.initials: S
authors.lastname: Buche
authors.forename: S
authors.initials: S
authors.lastname: Coopman
authors.forename: D
authors.initials: D
authors.lastname: Basraoui
authors.forename: D
authors.initials: D
authors.lastname: Turck
authors.forename: E
authors.initials: E
authors.lastname: Delaporte
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D003082:Colectomy; D003093:Colitis, Ulcerative / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D004872:Ergocalciferols / Q000627:therapeutic use; D006471:Gastrointestinal Hemorrhage / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000069285:Infliximab; D008171:Lung Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D009853:Omeprazole / Q000627:therapeutic use; D011183:Postoperative Complications / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology; D011349:Proctitis / Q000150:complications / Q000188:drug therapy / Q000601:surgery; D017511:Pyoderma Gangrenosum / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D014057:Tomography, X-Ray Computed
chemical_list: D000305:Adrenal Cortex Hormones; D000700:Analgesics; D000911:Antibodies, Monoclonal; D004872:Ergocalciferols; D007166:Immunosuppressive Agents; D000069285:Infliximab; D009853:Omeprazole